SCHEMBL2346359

SCHEMBL2346359

CCN1CCN(c2cccc3c2CNC3=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.46
DRD3 P35462 2/20 0.46
HTR6 P50406 2/20 0.46
HRH3 Q9Y5N1 1/20 0.46
CDK5 Q00535 2/20 0.45
DYRK1A Q13627 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
PIM1 P11309 1/20 0.45
CSNK1A1 P48729 1/20 0.45
ROCK1 Q13464 1/20 0.45
LRRK2 Q5S007 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
HTR2A P28223 6/20 0.43
HTR1A P08908 5/20 0.43
CHRNA7 P36544 1/20 0.41
LTK P29376 1/20 0.40
MST1R Q04912 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2346037 0.80 CDK5 (0.50) DRD2DRD3HTR6CDK5DYRK1A
SCHEMBL30843943 0.80 CDK5 (0.50) DRD2DRD3HTR6CDK5DYRK1A
SCHEMBL30775367 0.78 L3MBTL1 (0.52) DRD2CDK5DYRK1ACLK4PIM1
SCHEMBL2348607 0.75 DRD2 (0.46) DRD2DRD3HTR6HRH3CHRNA7
SCHEMBL12219092 0.71 CDK5 (0.58) CDK5DYRK1ACLK4PIM1CSNK1A1
Hydrochloric Acid SCHEMBL11198122 0.70 DRD2 (0.55) DRD2DRD3HTR6HRH3HTR2A
SCHEMBL21744256 0.69 DRD2 (0.47) DRD2DRD3HTR6HRH3CHRNA7
SCHEMBL11096500 0.69 CHRNA7 (0.59) DRD2DRD3HTR6HRH3CHRNA7
SCHEMBL5201380 0.69 DRD3 (0.54) DRD2DRD3HTR6HRH3
SCHEMBL29698264 0.68 PARP1 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445514-B2 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2013-05-21 US disclosed
US-20110269768-A1 UROTENSIN II RECEPTOR ANTAGONISTS KINNEY WILLIAM A 2011-11-03 US disclosed
US-8008299-B2 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (FR) 2011-08-30 US disclosed
US-20080318973-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269768-A1 UROTENSIN II RECEPTOR ANTAGONISTS UTS2R, BDKRB2, AGTR2 DRD2 581/4885DRD3 1250/4885HTR6 830/4885
US-20080318973-A1 Urotensin II receptor antagonists UTS2R, BDKRB2, AGTR2 DRD2 581/4885DRD3 1250/4885HTR6 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.